Medicines for Europe calls for pharma supply chain remedies as COVID-19 pandemic worsens

16 Mar 2020

As the global coronavirus pandemic worsens, generics industry association Medicines for Europe has called for all available European pharmaceutical manufacturing to remain open and running at all times and highlighted the risks to the supply chain that stoppages pose.

“If a region is struck by an outbreak, we must keep medicine factories open with additional hygiene/control measures,” the European generics industry association said. “Any stoppage creates a risk in the supply chain and heightens the risk of medicines shortages. We also need access to essential equipment like protective clothing or filters. We need solutions for employees to keep working if schools close or if there are restrictions on the movement of people.”

Medicines for Europe calls for pharma supply chain remedies as COVID-19 pandemic worsens

Medicines for Europe also said it was important that there are no export restrictions on manufacturers of medicines and active pharmaceutical ingredients (APIs), hoarding of supplies should be strongly discouraged and green lanes for cross-border transport of medicines should be set up as soon as possible not just between European countries but also between the EU and the US.

The association also called for clear regulatory guidance to counter the continued stress on global supply chains that arises out of production and logistics issues.

“Medicines for Europe has outlined the measures that could be taken to deal with any specific constraints and to keep manufacturing going at full speed,” it said.

Finally, the association said its members are analysing the possible future scenarios of the spread of the virus to plan for possible future surges in demand.

“We will work to continue supplying chronic disease medicines while also planning for additional emergency medicines production or importation,” it said.

Related news

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

23 Jun 2020

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

Read more 
CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

23 Jun 2020

The amended manufacturing agreement, which originally specified CordenPharma facilities Switzerland, now extends to the CDMOs France and US sites.

Read more 
TraceLink announces results from FDA DSCSA Pilot Program

TraceLink announces results from FDA DSCSA Pilot Program

23 Jun 2020

Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.

Read more 
FDA approves new Dupixent prefilled pen

FDA approves new Dupixent prefilled pen

23 Jun 2020

The prefilled pen supports more convenient self-administration for patients with chronic type 2 inflammatory diseases.

Read more 
Piramal acquires solid oral dosage drug product facility from G&W Laboratories

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

22 Jun 2020

The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.

Read more 
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

22 Jun 2020

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
Pharma packaging companies commit to supply for COVID-19 fight

Pharma packaging companies commit to supply for COVID-19 fight

16 Jun 2020

Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.

Read more 
BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology

BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology

16 Jun 2020

Novel platform initially focussed on high-resolution industrial-scale processing of therapeutic mRNA.

Read more 
Pharma’s supply chain prepares for the ‘next normal’ in a post-COVID-19 world

Pharma’s supply chain prepares for the ‘next normal’ in a post-COVID-19 world

15 Jun 2020

Supply chain executives request greater visibility and transparency, especially at the supplier and manufacturer level.

Read more